(Q78128686)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10448294%20AND%20SRC:MED&resulttype=core&format=json

11 December 2019

title

Relationship between diagnosis-specific activity of cytotoxic drugs in fresh human tumour cells ex vivo and in the clinic (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10448294%20AND%20SRC:MED&resulttype=core&format=json

11 December 2019

author name string

H Fridborg

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10448294%20AND%20SRC:MED&resulttype=core&format=json

11 December 2019

E Jonsson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10448294%20AND%20SRC:MED&resulttype=core&format=json

11 December 2019

P Nygren

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10448294%20AND%20SRC:MED&resulttype=core&format=json

11 December 2019

R Larsson

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10448294%20AND%20SRC:MED&resulttype=core&format=json

11 December 2019

publication date

1 March 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10448294%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Cancer

11 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10448294%20AND%20SRC:MED&resulttype=core&format=json

11 December 2019

volume

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10448294%20AND%20SRC:MED&resulttype=core&format=json

11 December 2019

page(s)

424-432

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10448294%20AND%20SRC:MED&resulttype=core&format=json

11 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10448294%20AND%20SRC:MED&resulttype=core&format=json

Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA)

11 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900286-X

7 January 2021

Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA).

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900286-X

7 January 2021

In vitro drug sensitivity testing of tumor cells from patients with non-Hodgkin's lymphoma using the fluorometric microculture cytotoxicity assay

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900286-X

7 January 2021

In vitro determination of cytotoxic drug response in ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA)

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900286-X

7 January 2021

Detection of tumor-specific cytotoxic drug activity in vitro using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900286-X

7 January 2021

In vitro activity of 2-chlorodeoxyadenosine (CdA) in primary cultures of human haematological and solid tumours.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900286-X

7 January 2021

Activity of cyclosporins as resistance modifiers in primary cultures of human haematological and solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900286-X

7 January 2021

The cytotoxic activity of Taxol in primary cultures of tumour cells from patients is partly mediated by Cremophor EL.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900286-X

7 January 2021

Selective sensitivity of solid tumors to suramin in primary cultures of tumor cells from patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900286-X

7 January 2021

Cytotoxic activity of calcein acetoxymethyl ester (Calcein/AM) on primary cultures of human haematological and solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900286-X

7 January 2021

Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900286-X

7 January 2021

m-AMSA: a review of clinical data

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900286-X

7 January 2021

High-dose cytosine arabinoside in non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900286-X

7 January 2021

High-dose cytosine arabinoside. Active agent in treatment of non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900286-X

7 January 2021

Cytosine arabinoside (NSC 63878) toxicity and antitumor acitivity in human solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900286-X

7 January 2021

A phase II trial of mitomycin in patients with epithelial ovarian carcinoma resistant to cisplatin or carboplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900286-X

7 January 2021

Mitomycin C (MCC) in advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900286-X

7 January 2021

Phase II trial of vincristine infusion in acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900286-X

7 January 2021

Etoposide (VP-16-213)

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900286-X

7 January 2021

Etoposide single-agent chemotherapy for solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900286-X

7 January 2021

Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900286-X

7 January 2021

Phase II trial of idarubicin in patients with advanced lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900286-X

7 January 2021

Phase-II trial of 4-demethoxydaunorubicin (DMDR) for advanced hypernephroma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900286-X

7 January 2021

Phase II clinical and pharmacological study of oral 4-demethoxydaunorubicin in advanced non-pretreated small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900286-X

7 January 2021

Paclitaxel (Taxol): a novel anticancer chemotherapeutic drug

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900286-X

7 January 2021

A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas. A Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900286-X

7 January 2021

Phase I trial of paclitaxel in children with refractory solid tumors: a Pediatric Oncology Group Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900286-X

7 January 2021

Vinorelbine. A review of its pharmacological properties and clinical use in cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900286-X

7 January 2021

Phase II study of navelbine in advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900286-X

7 January 2021

Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900286-X

7 January 2021

Correlations between therapeutic response of leukaemias and in-vitro drug-sensitivity assay

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900286-X

7 January 2021

Differential activity of Cremophor EL and paclitaxel in patients' tumor cells and human carcinoma cell lines in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900286-X

7 January 2021

Cladribine (2-chlorodeoxyadenosine)

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900286-X

7 January 2021

Chemotherapy of non-small cell lung carcinoma guided by an in vitro drug resistance assay measuring total tumour cell kill

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900286-X

7 January 2021

A critical appraisal of the predictive value of in vitro chemosensitivity assays.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900286-X

7 January 2021

Ex vivo cytotoxic drug evaluation by DiSC assay to expedite identification of clinical targets: results with 8-chloro-cAMP.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900286-X

7 January 2021

10.1016/S0959-8049(98)00286-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10448294%20AND%20SRC:MED&resulttype=core&format=json

11 December 2019

1 reference